Emerging therapeutics for Alzheimer's disease
Emma R L C Vardy1, Ishrut Hussain, Nigel M Hooper
1University of Leeds, Academic Unit of Molecular Vascular Medicine, Leeds Institute of Genetics, Health and Therapeutics, Clarendon Way, Leeds LS2 9JT, UK. medev@medphysics.leeds.ac.uk
Expert Review of Neurotherapeutics
|June 1, 2006
Summary
Alzheimer's disease (AD) treatments offer modest cognitive gains. Future therapies target amyloid plaques, neurofibrillary tangles, and neuroinflammation for better outcomes.
Area of Science:
- Neuroscience and Neurology
- Pharmacology and Drug Discovery
Background:
- Alzheimer's disease (AD) is the most prevalent form of dementia, with rising prevalence and socioeconomic impact.
- Current AD medications provide limited cognitive benefits.
- Understanding AD's pathology is accelerating the identification of novel therapeutic targets.
Purpose of the Study:
- To review current and future therapeutic strategies for Alzheimer's disease.
- To examine interventions targeting key pathological hallmarks of AD.
Main Methods:
- Review of existing literature on Alzheimer's disease pathology and therapeutic targets.
- Detailed consideration of interventions for amyloid-beta deposition, neurofibrillary tangles, and neuroinflammation.
- Exploration of potential future therapeutic mechanisms.
Main Results:
- Key pathological events in AD include amyloid-beta peptide (Abeta) deposition, neurofibrillary tangles, and neuroinflammation, leading to neuronal death.
- A variety of therapeutic approaches are under investigation for each pathological hallmark.
- Emerging mechanisms offer potential for future intervention.
Conclusions:
- Significant research is focused on developing new treatments for Alzheimer's disease.
- Targeting the core pathologies of AD holds promise for future therapeutic success.
- Continued investigation into novel mechanisms is crucial for advancing AD treatment.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...